Trial Profile
Multicenter, Randomized, Parallel Group Study to Compare the Incidence of Tocilizumab Related Infusion Reactions in Patients With Moderate to Severe Active RA, When Infusion is Given Over 31 Minutes Compared to 1 Hour
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms ACT-FAST
- Sponsors Roche
- 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 May 2013 Planned end date changed from 1 Jun 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 07 Nov 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).